What are Collegium Pharmaceutical, Inc.'s total assets?

Collegium Pharmaceutical, Inc. (COLL) holds $1.7B in total assets, up 1.3% year over year.

How much debt does Collegium Pharmaceutical, Inc. have?

Collegium Pharmaceutical, Inc. carries $5.2M in total debt against $312.4M of shareholders' equity, a debt-to-equity ratio of 0.02.

How much cash does Collegium Pharmaceutical, Inc. have?

Collegium Pharmaceutical, Inc. holds $289.6M in cash and equivalents.

Can Collegium Pharmaceutical, Inc. cover its short-term obligations?

Its current ratio is 1.71 — current assets exceed current liabilities.

Where does Collegium Pharmaceutical, Inc.'s balance sheet data come from?

Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Collegium Pharmaceutical, Inc. COLL Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$252.16M+161%	$96.61M-59.6%	$238.95M+37.6%	$173.69M-6.8%
Short-term investments	$155.43M+68.6%	$92.2M+28.8%	$71.6M—	$0—
Restricted cash	$19.85M-20.6%	$25M+2,288%	$1.05M-58.9%	$2.55M0.0%
Accounts receivable, net	$211.33M-7.5%	$228.54M+27.3%	$179.53M-2.0%	$183.12M+73.0%
Inventories	$14.01M-60.6%	$35.56M+10.0%	$32.33M-30.5%	$46.5M+167%
Raw materials	$18.96M—	——	——	——
Work in process	$15.09M—	——	——	——
Finished goods	$20.87M—	——	——	——
Prepaid expenses and other current assets	$32.64M+7.4%	$30.39M+100%	$15.2M-8.9%	$16.68M+184%
Trading assets	$52.08M—	——	——	——
Total current assets	$691.41M+43.4%	$482.26M-10.3%	$537.6M+28.0%	$419.99M+33.1%
Property and equipment, net	$12.01M-16.2%	$14.33M-10.3%	$15.98M-18.1%	$19.52M+0.2%
Accumulated depreciation	$916.66M—	——	——	——
Operating lease right-of-use assets	$4.19M-28.1%	$5.82M-3.4%	$6.03M-12.1%	$6.86M-10.2%
Goodwill	$145.93M-10.1%	$162.33M+21.3%	$133.86M+0.1%	$133.7M-50.2%
Intangible assets, net	$669.51M-24.9%	$891.4M+111%	$421.71M-25.7%	$567.47M+111%
Deferred tax assets	$398.65M+69.4%	$235.4M+134%	$100.57M-3.8%	$104.55M-48.7%
Other non-current assets	$20.19M+141%	$8.37M+914%	$825K+725%	$100K+14.9%
Available-for-sale securities	$103.35M—	——	——	——
Total assets	$1.66B-0.4%	$1.66B+45.5%	$1.14B-2.6%	$1.17B+69.7%
Accounts payable	$10.66M+171%	$3.93M-54.7%	$8.69M+149%	$3.49M-16.6%
Accrued expenses	$3.38M-95.3%	$72.12M+92.0%	$37.57M+4.0%	$36.13M+23.7%
Deferred revenue	$667K—	$0—	——	——
Operating lease liabilities, current	$1.41M+10.7%	$1.27M+28.6%	$988K-11.2%	$1.11M+36.6%
Contract liabilities	$9.11M-8.9%	$10M—	——	——
Income taxes payable	$3.3M—	——	——	——
Accrued interest	$12.02M—	——	——	——
Total current liabilities	$440.03M-13.6%	$509.51M+11.3%	$457.92M+5.6%	$433.73M+55.1%
Operating lease liabilities, non-current	$4.13M-25.4%	$5.54M-9.6%	$6.12M-13.9%	$7.11M-10.6%
Total liabilities	$1.36B-5.5%	$1.43B+51.4%	$947.88M-3.2%	$979.29M+100%
Preferred stock	$0—	$0—	——	——
Common stock	100M+249,900%	40K+5.3%	38K+2.7%	37K+2.8%
Additional paid-in capital	$624.95M+5.9%	$590.25M+4.3%	$565.95M+5.2%	$538.07M+7.2%
Retained earnings	-$101.13M+38.3%	-$164M+29.7%	-$233.19M+17.1%	-$281.34M-9.8%
Accumulated other comprehensive income (loss)	$319K+480%	$55K+293%	$14K—	——
Treasury stock	$222.51M+12.7%	$197.51M+43.8%	$137.38M+122%	$61.92M+44.5%
Total stockholders' equity	$301.68M+31.8%	$228.84M+17.1%	$195.43M+0.3%	$194.84M-4.0%
Total liabilities and stockholders' equity	$1.66B-0.4%	$1.66B+45.5%	$1.14B-2.6%	$1.17B+69.7%
Available-for-Sale Debt Securities - Amortized Cost	$155M—	——	——	——
Available-for-Sale Debt Securities - Fair Value by Maturity	$155.43M—	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	$155.43M—	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$155.43M—	——	——	——
Available For Sale Securities Debt Securities Current	$155.43M—	——	——	——
Short- term Investments	$155.43M+68.6%	$92.2M+28.8%	$71.6M—	$0—
Deferred Tax Assets and Other Non-Current Assets	$20.19M+141%	$8.37M+914%	$825K+725%	$100K+14.9%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	$1.59B—	——	——	——
Investments - Amortized Cost Basis	$155M—	——	——	——
Net Investment in Lease	$4.19M-28.1%	$5.82M-3.4%	$6.03M-12.1%	$6.86M-10.2%
Deferred tax assets	$112.54M+14.8%	$98.03M+273%	$26.26M+9.6%	$23.95M-69.3%
Intangible assets — net	$669.51M—	——	——	——
Other intangible assets—net	$669.51M-24.9%	$891.4M+111%	$421.71M-25.7%	$567.47M+111%
Operating lease right-of-use assets	$4.19M-28.1%	$5.82M-3.4%	$6.03M-12.1%	$6.86M-10.2%
Other non-current assets	$20.19M+141%	$8.37M+914%	$825K+725%	$100K+14.9%
Operating Lease Right-of-Use Assets in Other Assets	$4.19M-28.1%	$5.82M-3.4%	$6.03M-12.1%	$6.86M-10.2%
Software and Technology Licenses, Net	$20.19M+141%	$8.37M+914%	$825K+725%	$100K+14.9%
Accrued Manufacturing Costs	$3.38M—	——	——	——
Accrued Marketing and Advertising Expenses	$3.04M—	——	——	——
Accrued Progress Collections and Price Adjustments	$9.11M-8.9%	$10M—	——	——
Accrued Royalties (Current)	$7.99M—	——	——	——
Other Commercial Liabilities	$62.46M-13.4%	$72.12M+92.0%	$37.57M+4.0%	$36.13M+23.7%
Accrued Income Taxes, Current	$3.3M—	——	——	——
Accrued Liabilities, Current	$62.46M-13.4%	$72.12M+92.0%	$37.57M+4.0%	$36.13M+23.7%
Accrued rebates, returns and discounts	$318.27M-6.0%	$338.64M+49.0%	$227.33M-1.4%	$230.49M+17.0%
Compensation and benefits	$3.38M—	——	——	——
Current portion of mortgage and loans payable	$29M-55.1%	$64.58M-64.8%	$183.33M+12.8%	$162.5M+236%
Professional Service Fees Payable	$1.7M—	——	——	——
Contract Liabilities, Non-Current	$9.11M-8.9%	$10M—	——	——
Convertible Debt (Non-Current)	$238.21M+0.4%	$237.17M-9.5%	$262.13M+86.1%	$140.87M+0.6%
Marketing and selling	$3.04M—	——	——	——
Deferred revenue, net of current portion	$9.11M-8.9%	$10M—	——	——
Total debt	$5.54M-18.7%	$6.81M-4.2%	$7.11M-13.5%	$8.22M-6.2%
Common Stock Par Value Per Share	$0.00—	——	——	——
Common Stock Shares Issued	40.7M—	——	——	——
Convertible Preferred Stock Authorized Shares	5M—	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$41K+2.5%	$40K+5.3%	$38K+2.7%	$37K+2.8%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——	——
Preferred Stock Par Value Per Share	$0.00—	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Unrealized Gains on Investments	$492K—	——	——	——
Unrealized Losses on Investments (Before Tax)	$60K—	——	——	——
Cumulative Cost Basis	$155M—	——	——	——
Accrued bonuses	$9.17M—	——	——	——
Accrued incentive compensation	$3.71M—	——	——	——
Liability for cash-settled share-based awards assumed from Ironshore Acquisition	$2.44M—	——	——	——
Accrued inventory	$2.81M—	——	——	——
Accrued product taxes and fees	$7.73M—	——	——	——
Professional service fees	$1.7M—	——	——	——
Licensing Arrangements	$7.99M—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$60K—	——	——	——
Gross Unrealized Gains	$492K—	——	——	——
Total	$155M—	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$103.35M—	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$52.08M—	——	——	——
Available for sale investments	$155.43M—	——	——	——
Common stock, par value (in dollars per share)	$0—	——	——	——
Common stock, shares authorized (in shares)	$100M—	——	——	——
Common stock, shares issued (in shares)	$40.74M—	——	——	——
Common Stock, Shares, Outstanding	$31.71M—	——	——	——
Long-term debt, net	$238.21M+0.4%	$237.17M-9.5%	$262.13M+86.1%	$140.87M+0.6%
Deferred royalty obligation	$121.56M+0.8%	$120.61M—	——	——
Fair value of deferred royalty obligation	——	——	——	——
Effective interest rate	——	——	——	——
Cost not yet recognized	——	——	——	——
Thereafter	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$916.66M—	——	——	——
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Gross Carrying Amount	$1.59B—	——	——	——
Inventory, Current and Noncurrent	$54.93M—	——	——	——
Raw materials	$18.96M—	——	——	——
Loans Payable, Noncurrent	$542.11M-1.6%	$550.73M+148%	$221.71M-44.2%	$397.58M+545%
Other accrued liabilities	$5.17M—	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0—	——	——	——
Preferred Stock, Shares Authorized	$5M—	——	——	——
Treasury stock, shares (in shares)	$9.03M—	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Collegium Pharmaceutical, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Collegium Pharmaceutical, Inc.'s total assets?: Collegium Pharmaceutical, Inc. (COLL) holds $1.7B in total assets, up 1.3% year over year.
How much debt does Collegium Pharmaceutical, Inc. have?: Collegium Pharmaceutical, Inc. carries $5.2M in total debt against $312.4M of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Collegium Pharmaceutical, Inc. have?: Collegium Pharmaceutical, Inc. holds $289.6M in cash and equivalents.
Can Collegium Pharmaceutical, Inc. cover its short-term obligations?: Its current ratio is 1.71 — current assets exceed current liabilities.
Where does Collegium Pharmaceutical, Inc.'s balance sheet data come from?: Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.